Skyhawk's SAB Chair Honored with ACS Medal of Honor
Event summary
- Dr. Tyler Jacks, founding chairman of Skyhawk's Scientific Advisory Board, received the American Cancer Society's 2026 Medal of Honor on March 30, 2026.
- Dr. Jacks is a pioneer in developing genetically engineered mouse models for studying human cancers.
- He has authored over 300 scientific papers and served in key roles at the National Cancer Institute and AACR.
- Skyhawk Therapeutics uses its SKYSTAR® platform to develop small molecule RNA modulating therapies.
The big picture
The recognition of Dr. Tyler Jacks underscores the strategic importance of RNA modulation in cancer therapy. Skyhawk's focus on intractable diseases positions it within a competitive biotech landscape where scientific advisory boards with proven track records are critical for securing funding and partnerships. The Medal of Honor highlights the intersection of academic research and commercial biotechnology, potentially attracting more collaborators and investors to Skyhawk's platform.
What we're watching
- Scientific Leadership
- How Dr. Jacks' continued involvement will influence Skyhawk's RNA research pipeline.
- Industry Recognition
- Whether this honor enhances Skyhawk's credibility and partnerships in cancer research.
- Therapeutic Development
- The pace at which Skyhawk can translate its SKYSTAR® platform into clinical successes.
Related topics